Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

BioClinica Advances Standards Support at DIA 2009

By Drug Discovery Trends Editor | June 23, 2009

Bio-Imaging Technologies, Inc., d/b/a BioClinica, a global provider of clinical trial services, is challenging the industry to increase standards implementation for clinical trials at the Drug Information Association (DIA) 45th Annual Meeting on June 21-25 in San Diego (booth #315). Standards support has quickly become a key focus for the life science industry to streamline the clinical trial process and reduce costs. However, the complexity of the task and the resource requirements put implementing standards on the ‘someday list’ for many companies.

“Applicable standards are fully ready for use right now, making it vital that life science companies move forward with implementation,” said Mark Weinstein, President and CEO of BioClinica. “Unfortunately, this is often a difficult undertaking, especially when plates are full and budgets are challenged. Nevertheless, implementing clinical data standards will ultimately reduce costs and increase efficiency. We believe partners that understand clinical processes and standards are essential.”

Standards to support the acquisition, exchange and submission of clinical research data are paramount to increase the affordability and accessibility of medical research and improve the clinical trial process. Life science companies should prioritize incorporation of these standards into their data management practices to gain a competitive advantage, simplify processes and decrease costs during the clinical trial process. Vendor partners can play a vital role to assist their clients to stay ahead of the curve and reap the rewards.

“The time has come to use technology more strategically,” continued Weinstein. “The clinical research process will become more efficient only when we collectively support the development of standards, as well as their widespread adoption and implementation.”

Date: June 19, 2009
Source: Bioclinica


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50